138 related articles for article (PubMed ID: 31385026)
21. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
22. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
23. Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
Azzalini E; Barbazza R; Stanta G; Giorda G; Bortot L; Bartoletti M; Puglisi F; Canzonieri V; Bonin S
Gynecol Oncol; 2021 Dec; 163(3):498-505. PubMed ID: 34602289
[TBL] [Abstract][Full Text] [Related]
24. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma.
Kojima N; Yoshida H; Kuno I; Uehara T; Uno M; Ishikawa M; Kato T
Cancer Med; 2019 Aug; 8(10):4598-4604. PubMed ID: 31243928
[TBL] [Abstract][Full Text] [Related]
26. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
27. [Expressions and clinical significances of paired box gene 2 and cyclin D1 in advanced ovarian serous carcinoma].
Song Y; Zuo J; Huang X; Shen GH; Liu XY; Zhang X
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):891-895. PubMed ID: 29262504
[No Abstract] [Full Text] [Related]
28. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
31. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
32. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer.
Grabowski JP; Martinez Vila C; Richter R; Taube E; Plett H; Braicu E; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):498-503. PubMed ID: 31996397
[TBL] [Abstract][Full Text] [Related]
33. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
34. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
35. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
36. Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer.
Londero AP; Orsaria M; Tell G; Marzinotto S; Capodicasa V; Poletto M; Vascotto C; Sacco C; Mariuzzi L
Am J Clin Pathol; 2014 Mar; 141(3):404-14. PubMed ID: 24515769
[TBL] [Abstract][Full Text] [Related]
37. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
38. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor receptor 4 as a potential prognostic and therapeutic marker in colorectal cancer.
Li CS; Zhang SX; Liu HJ; Shi YL; Li LP; Guo XB; Zhang ZH
Biomarkers; 2014 Feb; 19(1):81-5. PubMed ID: 24410190
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Role of Optimal Cytoreduction in Advanced, Bowel Infiltrating Ovarian Cancer.
Bachmann R; Rothmund R; Krämer B; Brucker SY; Königsrainer A; Königsrainer I; Beckert S; Staebler A; NguyenHuu P; Grischke E; Wallwiener D; Bachmann C
J Invest Surg; 2015 Jun; 28(3):160-6. PubMed ID: 25565126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
